CLVLY is one of the most undervalued stocks right now and it won't last for many months. Many investors have been in Clinuvel for 5-10 years and the recent EMA approval of Scenesse was a historic event. But this is merely the start. The World hasn't yet recognized the potential Afamelanotide holds. EPP is only a proof of concept and many indications will follow soon. Today, the PPS ought to be app. 10 USD based in a very conservative valuation. Europe has around 4500 EPP patients. Let's assume 50 % turn to Scenesse. That's extremely conservative given the huge support the patients have shown. Actually, they were instrumental in getting the implant approved by the CHMP. Cost per year is up to 28.000 USD. That's 63 million in revenues. Conservatively. Clinuvel is going to self distribute so let's say 60 million after marketing expenses. A p/s ratio of 5 (very conservative) and we arrive at a PPS of app. 7 USD. (60 m x 5 / 42 m s.o.) That's without FDA approval which is 98 % sure. Then add at least 50 % of the European revenues and we arrive at 10 USD PPS.
Now, EPP is only a foot in the door. Clinuvel will be dominating the World market for photoprotection within few years. Imagine all the conditions that will benefit from UV protection. PMLE, SU etc. HHD is already in Phase 2b and has shown remarkable results. And then there is the big one: Vitiligo.
Clinuvel is conducting its phase 2b in Singapore right now and there is huge academic support for that indication as well. Potential revenues (conservatively) could very well exceed 1 bn per year after expenses. That's a market cap of 5 bn for Vitiligo alone with a p/s ratio of 5. But when the World realizes that there is a melanocirtin implant on the market that gives you a healthy tan and that it can cure and treat a huge number of dermatological conditions emotions will also drive this stock higher. After all, this is historic. Never before has Afamelanotide been approved by regulators and only a very naive person can't see the potential. Eventually, this is the perfect protectant against skin cancer. A healthy tan without having been exposed to UV. Revolutionary.
Then there is the potent antiinflammatory effect Scenesse has.
Add Acne, Psoreasis, Rossacea and the market cap will be + 10 bn. Probably way more.
Very few stocks offers the potential Clinuvel does. Longs have known that for a decade and I invite you to visit ShareScene or our CUV Google Group.
When the World wakes up and sees the potential in this remarkable company this group will also get going. But it will probably take some months. Until then, if you read this you are one of the very lucky few to begin your DD before the big run.
